Trial
NCT05639543
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Intercept Pharmaceuticals
Collaborators
—
Condition
Alcohol Associated Hepatitis
Intervention
INT-787
Why stopped
Intercept made the business decision to terminate the study on 31 Mar 2026 as there was no clear evidence of potential benefit of INT-787 in sAH. This decision was not based on a safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-05